Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 235

The DOI matches its Crossref record; 61 of the 61 references it cites were found in a registry or an index.

Molecular Mechanisms of Hepcidin Regulation: Implications for the Anemia of CKD

Open access
Babitt, Jodie L., Lin, Herbert Y. · 2010 · American Journal of Kidney Diseases

Abstract

Anemia is prevalent in patients with chronic kidney disease (CKD) and is associated with a lower quality of life and a higher risk of adverse outcomes including cardiovascular disease and death. Anemia management in CKD patients currently revolves around the use of erythropoiesis-stimulating agents (ESAs) and supplemental iron. However, many patients do not respond adequately and/or require high doses of these medications. Furthermore, recent clinical trials have shown that targeting higher hemoglobin levels with conventional therapies leads to increased cardiovascular morbidity and mortality, particularly when higher doses of ESAs are used, and in patients who are poorly responsive to therapy. One explanation for the poor response to conventional therapies in some patients is that these treatments do not fully address the underlying cause of the anemia. In many CKD patients, like patients with other chronic inflammatory diseases, poor absorption of dietary iron and inability to utilize the body's iron stores contributes to the anemia. Recent research suggests that these abnormalities in iron balance may be caused by elevated levels of the key iron regulatory hormone hepcidin. This article reviews the pathogenesis of anemia in CKD, the role and regulation of hepcidin in systemic iron homeostasis and the anemia of CKD, and the potential diagnostic and therapeutic implications of these findings.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1053/j.ajkd.2009.12.030

Cites

61 of 61 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 61 references

Research works printed but not linked: 88

  1. Szczech, 2008, Secondary analysis of the CHOIR trial epoetin-alpha dose and achieved hemoglobin outcomes, Kidney Int., 74, 791, 10.1038/ki.2008.295 · DOI · Paper page
  2. Malyszko, 2007, Hepcidin in anemia and inflammation in chronic kidney disease, Kidney Blood Press Res., 30, 15, 10.1159/000098522 · DOI
  3. Macdougall, 1996, A randomized controlled study of iron supplementation in patients treated with erythropoietin, Kidney Int., 50, 1694, 10.1038/ki.1996.487 · DOI · Paper page
  4. Fudin, 1998, Correction of uremic iron deficiency anemia in hemodialyzed patients: a prospective study, Nephron, 79, 299, 10.1159/000045053 · DOI
  5. Markowitz, 1997, An evaluation of the effectiveness of oral iron therapy in hemodialysis patients receiving recombinant human erythropoietin, Clin Nephrol., 48, 34
  6. Eleftheriadis, 2007, Disturbances of acquired immunity in hemodialysis patients, Semin Dial., 20, 440, 10.1111/j.1525-139X.2007.00283.x · DOI · Paper page
  7. Ganz, 2008, Immunoassay for human serum hepcidin, Blood, 112, 4292, 10.1182/blood-2008-02-139915 · DOI · Paper page
  8. Ashby, 2009, Plasma hepcidin levels are elevated but responsive to erythropoietin therapy in renal disease, Kidney Int., 75, 976, 10.1038/ki.2009.21 · DOI · Paper page
  9. Zaritsky, 2009, Hepcidin—a potential novel biomarker for iron status in chronic kidney disease, Clin J Am Soc Nephrol., 4, 1051, 10.2215/CJN.05931108 · DOI · Paper page
  10. Ramey, 2009, Hepcidin targets ferroportin for degradation in hepatocytes, Haematologica
  11. Nicolas, 2002, Severe iron deficiency anemia in transgenic mice expressing liver hepcidin, Proc Natl Acad Sci U S A, 99, 4596, 10.1073/pnas.072632499 · DOI · Paper page
  12. Nemeth, 2003, Hepcidin, a putative mediator of anemia of inflammation, is a type II acute-phase protein, Blood, 101, 2461, 10.1182/blood-2002-10-3235 · DOI · Paper page
  13. Pietrangelo, 2006, Hereditary hemochromatosis, Biochim Biophys Acta., 1763, 700, 10.1016/j.bbamcr.2006.05.013 · DOI
  14. Kawabata, 1999, Molecular cloning of transferrin receptor 2, J Biol Chem., 274, 20826, 10.1074/jbc.274.30.20826 · DOI · Paper page
  15. Bridle, 2003, Disrupted hepcidin regulation in HFE-associated haemochromatosis and the liver as a regulator of body iron homoeostasis, Lancet, 361, 669, 10.1016/S0140-6736(03)12602-5 · DOI · Paper page
  16. Nemeth, 2005, Hepcidin is decreased in TFR2 hemochromatosis, Blood, 105, 1803, 10.1182/blood-2004-08-3042 · DOI · Paper page
  17. Huang, 2005, A mouse model of juvenile hemochromatosis, J Clin Invest., 115, 2187, 10.1172/JCI25049 · DOI · Paper page
  18. Niederkofler, 2005, Hemojuvelin is essential for dietary iron sensing, and its mutation leads to severe iron overload, J Clin Invest., 115, 2180, 10.1172/JCI25683 · DOI · Paper page
  19. Kawabata, 2005, Expression of hepcidin is down-regulated in TfR2 mutant mice manifesting a phenotype of hereditary hemochromatosis, Blood, 105, 376, 10.1182/blood-2004-04-1416 · DOI · Paper page
  20. Muckenthaler, 2003, Regulatory defects in liver and intestine implicate abnormal hepcidin and Cybrd1 expression in mouse hemochromatosis, Nat Genet., 34, 102, 10.1038/ng1152 · DOI · Paper page
  21. Wallace, 2005, First phenotypic description of transferrin receptor 2 knockout mouse, and the role of hepcidin, Gut, 54, 980, 10.1136/gut.2004.062018 · DOI · Paper page
  22. Wang, 2005, A role of SMAD4 in iron metabolism through the positive regulation of hepcidin expression, Cell Metab., 2, 399, 10.1016/j.cmet.2005.10.010 · DOI · Paper page
  23. Shi, 2003, Mechanisms of TGF-beta signaling from cell membrane to the nucleus, Cell, 113, 685, 10.1016/S0092-8674(03)00432-X · DOI · Paper page
  24. Babitt, 2007, Modulation of bone morphogenetic protein signaling in vivo regulates systemic iron balance, J Clin Invest., 117, 1933, 10.1172/JCI31342 · DOI · Paper page
  25. Xia, 2008, Hemojuvelin regulates hepcidin expression via a selective subset of BMP ligands and receptors independently of neogenin, Blood, 111, 5195, 10.1182/blood-2007-09-111567 · DOI · Paper page
  26. Truksa, 2007, Different regulatory elements are required for response of hepcidin to interleukin-6 and bone morphogenetic proteins 4 and 9, Br J Haematol., 139, 138, 10.1111/j.1365-2141.2007.06728.x · DOI
  27. Truksa, 2009, Two BMP responsive elements, STAT, and bZIP/HNF4/COUP motifs of the hepcidin promoter are critical for BMP, SMAD1, and HJV responsiveness, Blood, 113, 688, 10.1182/blood-2008-05-160184 · DOI
  28. Island, 2009, A new mutation in the hepcidin promoter impairs its BMP response and contributes to a severe phenotype in HFE related hemochromatosis, Haematologica, 94, 720, 10.3324/haematol.2008.001784 · DOI
  29. Yu, 2008, Dorsomorphin inhibits BMP signals required for embryogenesis and iron metabolism, Nat Chem Biol., 4, 33, 10.1038/nchembio.2007.54 · DOI · Paper page
  30. Meynard, 2009, Lack of the bone morphogenetic protein BMP6 induces massive iron overload, Nat Genet., 41, 478, 10.1038/ng.320 · DOI · Paper page
  31. Corradini, 2009, Bone morphogenetic protein signaling is impaired in a Hfe knockout mouse model of hemochromatosis, Gastroenterology, 137, 1489, 10.1053/j.gastro.2009.06.057 · DOI
  32. Bennett, 2000, Crystal structure of the hereditary haemochromatosis protein HFE complexed with transferrin receptor, Nature, 403, 46, 10.1038/47417 · DOI · Paper page
  33. West, 2001, Mutational analysis of the transferrin receptor reveals overlapping HFE and transferrin binding sites, J Mol Biol., 313, 385, 10.1006/jmbi.2001.5048 · DOI
  34. Vujić Spasić, 2008, Hfe acts in hepatocytes to prevent hemochromatosis, Cell Metab., 7, 173, 10.1016/j.cmet.2007.11.014 · DOI
  35. Wallace, 2007, Targeted disruption of the hepatic transferrin receptor 2 gene in mice leads to iron overload, Gastroenterology, 132, 301, 10.1053/j.gastro.2006.11.028 · DOI
  36. Pietrangelo, 2005, Juvenile hemochromatosis associated with pathogenic mutations of adult hemochromatosis genes, Gastroenterology, 128, 470, 10.1053/j.gastro.2004.11.057 · DOI
  37. Wallace, 2009, Combined deletion of Hfe and transferrin receptor 2 in mice leads to marked dysregulation of hepcidin and iron overload, Hepatology, 50, 1992, 10.1002/hep.23198 · DOI · Paper page
  38. Kautz, 2009, BMP/Smad signaling is not enhanced in Hfe-deficient mice despite increased Bmp6 expression, Blood, 114, 2515, 10.1182/blood-2009-02-206771 · DOI
  39. Calzolari, 2006, TfR2 localizes in lipid raft domains and is released in exosomes to activate signal transduction along the MAPK pathway, J Cell Sci., 119, 4486, 10.1242/jcs.03228 · DOI · Paper page
  40. Ramey, 2009, Cross-talk between the mitogen activated protein kinase and bone morphogenetic protein/hemojuvelin pathways is required for the induction of hepcidin by holotransferrin in primary mouse hepatocytes, Haematologica, 94, 765, 10.3324/haematol.2008.003541 · DOI
  41. Lee, 2005, Regulation of hepcidin transcription by interleukin-1 and interleukin-6, Proc Natl Acad Sci U S A, 102, 1906, 10.1073/pnas.0409808102 · DOI · Paper page
  42. Zhang, 2006, Endoplasmic reticulum stress activates cleavage of CREBH to induce a systemic inflammatory response, Cell, 124, 587, 10.1016/j.cell.2005.11.040 · DOI · Paper page
  43. Oliveira, 2009, ER stress-inducible factor CHOP affects the expression of hepcidin by modulating C/EBPalpha activity, PLoS One, 4, e6618, 10.1371/journal.pone.0006618 · DOI
  44. Liu, 2005, Regulation of hepcidin and ferroportin expression by lipopolysaccharide in splenic macrophages, Blood Cells Mol Dis., 35, 47, 10.1016/j.bcmd.2005.04.006 · DOI · Paper page
  45. Koening, 2009, Toll-like receptors mediate induction of hepcidin in mice infected with Borrelia burgdorferi, Blood, 114, 1913, 10.1182/blood-2009-03-209577 · DOI
  46. Kuninger, 2006, Complex biosynthesis of the muscle-enriched iron regulator RGMc, J Cell Sci., 119, 3273, 10.1242/jcs.03074 · DOI
  47. Zhang, 2007, Evidence that inhibition of hemojuvelin shedding in response to iron is mediated through neogenin, J Biol Chem., 282, 12547, 10.1074/jbc.M608788200 · DOI
  48. Kuninger, 2008, Pro-protein convertases control the maturation and processing of the iron-regulatory protein, RGMc/hemojuvelin, BMC Biochem., 9, 9, 10.1186/1471-2091-9-9 · DOI
  49. Lin, 2008, Soluble hemojuvelin is released by proprotein convertase-mediated cleavage at a conserved polybasic RNRR site, Blood Cells Mol Dis., 40, 122, 10.1016/j.bcmd.2007.06.023 · DOI
  50. Zhang, 2005, Interaction of hemojuvelin with neogenin results in iron accumulation in human embryonic kidney 293 cells, J Biol Chem., 280, 33885, 10.1074/jbc.M506207200 · DOI
  51. Nicolas, 2002, Hepcidin, a new iron regulatory peptide, Blood Cells Mol Dis., 29, 327, 10.1006/bcmd.2002.0573 · DOI · Paper page
  52. Pinto, 2008, Erythropoietin mediates hepcidin expression in hepatocytes through EPOR signaling and regulation of C/EBPalpha, Blood, 111, 5727, 10.1182/blood-2007-08-106195 · DOI · Paper page
  53. Vokurka, 2006, Hepcidin mRNA levels in mouse liver respond to inhibition of erythropoiesis, Physiol Res., 55, 667, 10.33549/physiolres.930841 · DOI · Paper page
  54. Tanno, 2009, Identification of TWSG1 as a second novel erythroid regulator of hepcidin expression in murine and human cells, Blood, 114, 181, 10.1182/blood-2008-12-195503 · DOI · Paper page
  55. Oelgeschläger, 2000, The evolutionarily conserved BMP-binding protein Twisted gastrulation promotes BMP signalling, Nature, 405, 757, 10.1038/35015500 · DOI · Paper page
  56. Ross, 2001, Twisted gastrulation is a conserved extracellular BMP antagonist, Nature, 410, 479, 10.1038/35068578 · DOI · Paper page
  57. Chang, 2001, Twisted gastrulation can function as a BMP antagonist, Nature, 410, 483, 10.1038/35068583 · DOI · Paper page
  58. Xu, 2006, GDF15/MIC-1 functions as a protective and antihypertrophic factor released from the myocardium in association with SMAD protein activation, Circ Res., 98, 342, 10.1161/01.RES.0000202804.84885.d0 · DOI · Paper page
  59. Eling, 2006, NSAID activated gene (NAG-1), a modulator of tumorigenesis, J Biochem Mol Biol., 39, 649
  60. Braliou, 2008, 2-Oxoglutarate-dependent oxygenases control hepcidin gene expression, J Hepatol., 48, 801, 10.1016/j.jhep.2007.12.021 · DOI
  61. Tacchini, 1999, Transferrin receptor induction by hypoxia, J Biol Chem., 274, 24142, 10.1074/jbc.274.34.24142 · DOI · Paper page
  62. Mole, 2010, Iron homeostasis and its interaction with prolyl hydroxylases, Antioxid Redox Signal, 12, 445, 10.1089/ars.2009.2790 · DOI
  63. Shah, 2009, Intestinal hypoxia-inducible transcription factors are essential for iron absorption following iron deficiency, Cell Metab., 9, 152, 10.1016/j.cmet.2008.12.012 · DOI · Paper page
  64. Du, 2008, The serine protease TMPRSS6 is required to sense iron deficiency, Science, 320, 1088, 10.1126/science.1157121 · DOI · Paper page
  65. Finberg, 2008, Mutations in TMPRSS6 cause iron-refractory iron deficiency anemia (IRIDA), Nat Genet., 40, 569, 10.1038/ng.130 · DOI · Paper page
  66. Folgueras, 2008, Membrane-bound serine protease matriptase-2 (Tmprss6) is an essential regulator of iron homeostasis, Blood, 112, 2539, 10.1182/blood-2008-04-149773 · DOI · Paper page
  67. Velasco, 2002, Matriptase-2, a membrane-bound mosaic serine proteinase predominantly expressed in human liver and showing degrading activity against extracellular matrix proteins, J Biol Chem., 277, 37637, 10.1074/jbc.M203007200 · DOI · Paper page
  68. Truksa, 2009, Suppression of the hepcidin-encoding gene Hamp permits iron overload in mice lacking both hemojuvelin and matriptase-2/TMPRSS6, Br J Haematol., 147, 571, 10.1111/j.1365-2141.2009.07873.x · DOI
  69. Kemna, 2007, Mass spectrometry-based hepcidin measurements in serum and urine: analytical aspects and clinical implications, Clin Chem., 53, 620, 10.1373/clinchem.2006.079186 · DOI · Paper page
  70. Schranz, 2009, Activation and inactivation of the iron hormone hepcidin: biochemical characterization of prohepcidin cleavage and sequential degradation to N-terminally truncated hepcidin isoforms, Blood Cells Mol Dis., 43, 169, 10.1016/j.bcmd.2009.03.008 · DOI
  71. Gagliardo, 2009, Pro-hepcidin is unable to degrade the iron exporter ferroportin unless maturated by a furin-dependent process, J Hepatol., 50, 394, 10.1016/j.jhep.2008.09.018 · DOI
  72. Swinkels, 2008, Advances in quantitative hepcidin measurements by time-of-flight mass spectrometry, PLoS One, 3, e2706, 10.1371/journal.pone.0002706 · DOI · Paper page
  73. Peslova, 2009, Hepcidin, the hormone of iron metabolism, is bound specifically to alpha-2-macroglobulin in blood, Blood, 113, 6225, 10.1182/blood-2009-01-201590 · DOI
  74. Roe, 2007, Serum prohepcidin concentration: no association with iron absorption in healthy men; and no relationship with iron status in men carrying HFE mutations, hereditary haemochromatosis patients undergoing phlebotomy treatment, or pregnant women, Br J Nutr., 97, 544, 10.1017/S0007114507336829 · DOI
  75. Kemna, 2005, Time-course analysis of hepcidin, serum iron, and plasma cytokine levels in humans injected with LPS, Blood, 106, 1864, 10.1182/blood-2005-03-1159 · DOI · Paper page
  76. Tomosugi, 2006, Detection of serum hepcidin in renal failure and inflammation by using ProteinChip System, Blood, 108, 1381, 10.1182/blood-2005-10-4043 · DOI · Paper page
  77. Kemna, 2005, Novel urine hepcidin assay by mass spectrometry, Blood, 106, 3268, 10.1182/blood-2005-05-1873 · DOI
  78. Murphy, 2007, Quantitation of hepcidin from human and mouse serum using liquid chromatography tandem mass spectrometry, Blood, 110, 1048, 10.1182/blood-2006-11-057471 · DOI · Paper page
  79. Murao, 2007, Simple and sensitive quantification of bioactive peptides in biological matrices using liquid chromatography/selected reaction monitoring mass spectrometry coupled with trichloroacetic acid clean-up, Rapid Commun Mass Spectrom., 21, 4033, 10.1002/rcm.3319 · DOI
  80. Kobold, 2008, Quantification of hepcidin-25 in human serum by isotope dilution micro-HPLC-tandem mass spectrometry, Clin Chem., 54, 1584, 10.1373/clinchem.2008.107029 · DOI
  81. De Domenico, 2008, The hepcidin-binding site on ferroportin is evolutionarily conserved, Cell Metab., 8, 146, 10.1016/j.cmet.2008.07.002 · DOI
  82. Grebenchtchikov, 2009, High-sensitive radioimmunoassay for human serum hepcidin, Br J Haematol., 146, 317, 10.1111/j.1365-2141.2009.07758.x · DOI
  83. Koliaraki, 2009, A novel immunological assay for hepcidin quantification in human serum, PLoS One, 4, e4581, 10.1371/journal.pone.0004581 · DOI
  84. Kroot, 2009, Results of the first international round robin for the quantification of urinary and plasma hepcidin assays: need for standardization, Haematologica, 94, 1748, 10.3324/haematol.2009.010322 · DOI · Paper page
  85. Weiss, 2009, Serum hepcidin concentration in chronic haemodialysis patients: associations and effects of dialysis, iron and erythropoietin therapy, Eur J Clin Invest., 39, 883, 10.1111/j.1365-2362.2009.02182.x · DOI
  86. Peters, 2009, Serum hepcidin-25 levels in patients with chronic kidney disease are independent of glomerular filtration rate, Nephrol Dial Transplant.
  87. Kato, 2008, Association of prohepcidin and hepcidin-25 with erythropoietin response and ferritin in hemodialysis patients, Am J Nephrol., 28, 115, 10.1159/000109968 · DOI
  88. Swinkels, 2008, Hepcidin: a new tool in the management of anaemia in patients with chronic kidney disease?, Nephrol Dial Transplant., 23, 2450, 10.1093/ndt/gfn267 · DOI

Cited by

See all 235

Metadata

Authors
Babitt, J. L., & Lin, H. Y.
Venue
American Journal of Kidney Diseases
Publisher
Elsevier BV
Published
2010-04
Volume
55
Issue
4
Pages
726-741
ISSN
0272-6386 (ISSN-L)
OpenAlex
W2095421717
Cited by
235
References
61
FWCI
10.95
Type
journal article
Language
en
Open access
green
Licence
  • www.elsevier.com/tdm/userlicense/1.0/ (tdm)
  • www.elsevier.com/legal/tdmrep-license (tdm)

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Molecular Mechanisms of Hepcidin Regulation: Implications for the Anemia of CKD. https://app.cochat.ai/papers/10.1053/j.ajkd.2009.12.030
The paper
Babitt, J. L., & Lin, H. Y. (2010). Molecular Mechanisms of Hepcidin Regulation: Implications for the Anemia of CKD. American Journal of Kidney Diseases. https://doi.org/10.1053/j.ajkd.2009.12.030

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.